Ginkgo Bioworks price target lowered to $6 from $7 at BTIG
BTIG analyst Mark Massaro lowered the firm’s price target on Ginkgo Bioworks (DNA) to $6 from $7 and keeps a Sell rating on the shares ...
MM&M18h
Rx Rundown: Roche, Metsera, Intercept Pharmaceuticals and more
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
Ginkgo Bioworks Holdings Third Quarter 2024 Earnings: Beats Expectations
Revenue exceeded analyst estimates by 98%. Earnings per share (EPS) also surpassed analyst estimates by 67%. Looking ahead, ...
XWELL, Inc. Reports Third Quarter 2024 Results
XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today reported results for the third quarter ...